Chloramphenicol Inj Rx
Generic Name and Formulations:
Chloramphenicol sodium succinate 100mg/mL; pwd for IV inj after reconstitution; sodium content 2.25 mEq/g chloramphenicol; preservative-free.
Various generic manufacturers
Indications for Chloramphenicol Inj:
Serious susceptible infections resistant to other antibiotics. Typhoid fever. Cystic fibrosis regimens.
Give by IV inj over ≥1-minute interval. 50mg/kg per day in 4 divided doses every 6 hours. Moderately resistant infections: may increase up to 100mg/kg per day, reduce dose as soon as possible. Typhoid fever: give for 8–10 days after patient has become afebrile. Renal or hepatic impairment: adjust or reduce dose. Switch to oral form as soon as possible.
Give by IV inj over ≥1-minute interval. Premature, full-term infants <2 weeks old, or children with immature metabolic processes: 25mg/kg per day in 4 divided doses every 6 hours. Children >2 weeks old: up to 50mg/kg per day in 4 divided doses every 6 hours. Severe infections (eg, bacteremia, meningitis): up to 100mg/kg per day, reduce to 50mg/kg per day as soon as possible. Typhoid fever: give for 8–10 days after patient has become afebrile. Switch to oral form as soon as possible.
Not for trivial infections or prophylaxis. Previous toxic reactions to chloramphenicol.
Renal or hepatic impairment. Obtain baseline CBCs then every 2 days during therapy; discontinue if blood dyscrasias, optic neuritis or peripheral neuritis develops. Avoid repeat therapy. Monitor serum levels. Premature and newborn infants. Labor & delivery. Pregnancy. Nursing mothers.
Avoid other bone marrow suppressants.
Serious/fatal blood dyscrasias, paroxysmal nocturnal hemoglobinemia, GI upset, headache, confusion, delirium, optic and peripheral neuritis, gray baby syndrome, rashes, anaphylaxis, Herxheimer reactions (w. typhoid fever).
Formerly known under the brand names Chlormycetin, Mychel S.
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness